Discover your next big idea for life sciences at PACK EXPO Las Vegas
Experience a breakthrough in life sciences packaging—explore solutions from 2,300 suppliers spanning all industries, all in one place this September

Recipharm Secures Vaccine Manufacturing Deal

In accordance with the agreement, the company will aseptically pack single-use vaccines used to treat a severe infectious disease that affects both young children and infants.

Recipharm Pic

Global contract development and manufacturing organization Recipharm has inked a deal with a top 10 big pharma company to support vaccine manufacturing from its facility in Kaysersberg, France.

The agreement was announced following the successful quality audit and will see Recipharm aseptically pack single-use vaccines used to treat a severe infectious disease that affects both young children and infants.

The containers will be filled using Recipharm’s specialist blow/fill/seal capabilities (b/f/s), creating products that are quick to distribute and simplifying administration for healthcare providers.

Recipharm plans to recruit over 30 members of staff between 2022 and 2026 as the product scales toward commercial production.

Yves Buelens, general manager at Recipharm’s facility in Kaysersberg, says, “We are very proud to be supporting a big pharma partner in the delivery of a vital vaccine to the market.

“This deal is indicative of Recipharm’s successful and ongoing product portfolio diversification. We’ve invested heavily into new capabilities that have built on our b/f/s/ expertise and, as a result, strengthened our biotech offering. We are now in a position to welcome new biopharma projects to the Kaysersberg site.”

Recipharm is investing almost 14 million euros into its vaccine manufacturing offering at the site.

Located in the Alsace region of France, Kaysersberg is one of Recipharm’s specialist sterile manufacturing facilities which had been previously dedicated to the exclusive production of sterile liquids for therapeutic areas, including eye care and ear drops.

The facility has been inspected and approved by multiple regulatory agencies across the globe including ANSM (EU-GMP), FDA, and Brazil’s ANVISA. It also holds a number of approvals for its environmental management systems and occupational health and safety management system.


Fill out the form below to request more information about Recipharm Secures Vaccine Manufacturing Deal
Medical Device Innovations Report
Cutting-edge packaging technologies are transforming the medical device sector in PMMI’s “Innovation in Medical Device” report, featuring advanced materials, smart solutions, and evolving regulations. Editors share insights from nearly 300 PACK EXPO booth visits—each product deemed new and truly innovative—alongside video demonstrations of the equipment and materials on display.
Learn More
Medical Device Innovations Report
FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
FDA warning letters surge - is your team prepared?